Accelerating our strategic and financial development
AstraZeneca to acquire Alexion
Webinar and conference call for investors and analysts took place on Saturday 12 December 2020 14:00 GMT.
-
AstraZeneca appoints Aradhana Sarin as new Chief Financial Officer
-
AstraZeneca shareholders vote in favour of proposed acquisition of Alexion
-
AstraZeneca receives US clearance of proposed acquisition of Alexion
-
AstraZeneca to acquire Alexion, accelerating the Company's strategic and financial development
Competition clearances achieved in proposed acquisition of Alexion
Jurisdiction |
Date |
|---|---|
Brazil |
March |
Canada |
March |
Colombia |
March |
Morocco |
April |
Russia |
April |
Turkey |
April |
United States |
April |
Israel |
May |
Japan |
May |
Saudi Arabia |
May |
South Korea |
May |
Taiwan |
May |
, in each case as amended by any subsequent filings made with the SEC. These forward looking statements include all matters that are not historical facts and involve predictions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect AstraZeneca’s and Alexion’s current views with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to AstraZeneca’s or Alexion’s results of operations, financial position, liquidity, prospects, growth or strategies and the industries in which they operate. Forward-looking statements speak only as of the date they are made and cannot be relied upon as a guide to future performance. Save as required by law or regulation, AstraZeneca and Alexion disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements in this area of the website, whether as a result of new information, future events or otherwise. Nothing contained in this area of the website should be construed as a profit estimate or profit forecast and no statement in this area of the website should be interpreted to mean that earnings per share of AstraZeneca or Alexion for the current or future financial years would necessarily match or exceed the historical published earnings per share of AstraZeneca or Alexion. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.